Medline Inc. Class A common stock
Here’s whether Medline Inc. Class A common stock (MDLN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.45% over 10 days); 3-month momentum positive (+8.0%). Concerns: RSI 77 — overbought, elevated pullback risk; declining volume on rally — weak conviction (0.78x 30d avg). Currently 6.4% off its 52-week high. Score: +1/7.
MDLN is trading below its 200-day MA (—) — a key warning sign the longer-term trend is under pressure. With an RSI of 76.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. With ~4 months of trading history, the return since first available bar is +16.2%.